[1] |
XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
A systematic review of current advancements of artificial intelligence in genitourinary cancers
[J]. China Oncology, 2022, 32(1): 68-74.
|
[2] |
WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei .
Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
[J]. China Oncology, 2021, 31(7): 561-566.
|
[3] |
CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei.
The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
[J]. China Oncology, 2021, 31(6): 441-446.
|
[4] |
WANG Zhu, ZHANG Ying, ZHANG Jianwen, DENG Qiong, LIANG Hui.
Nuclear receptor HNF4α promotes castration-resistant prostate cancer via its regulation of androgen receptor expression
[J]. China Oncology, 2021, 31(3): 170-175.
|
[5] |
ZHANG Jinzhong , LI Yueqi , SHI Ke , YANG Liang , GUO Dan .
Expression and clinical significance of PLK4 gene in esophageal squamous cell carcinoma and its effect on cell proliferation, invasion and migration
[J]. China Oncology, 2021, 31(12): 1185-1193.
|
[6] |
BIAN Xiaojie, YE Dingwei.
New ideas of androgen deprivation therapy for prostate cancer: new progress in clinical research of testosterone maximum control
[J]. China Oncology, 2021, 31(12): 1209-1214.
|
[7] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|
[8] |
FAN Bo , QI Pan , SU Jianzhi , WEI Shufei , ZHANG Xuan , ZHANG Aili .
Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University
[J]. China Oncology, 2020, 30(8): 620-625.
|
[9] |
China Anti-Cancer Association Genitourinary Cancer Committee, Chinese Society of Clinical Oncology Committee on Prostate Cancer.
Chinese expert consensus on genomic testing of prostate cancer patients (the 2020 edition)
[J]. China Oncology, 2020, 30(7): 551-560.
|
[10] |
LI Zeng, LIAO Hong, MAO Dun, WU Yi, XIAO Yingming, YANG Shengke, ZHONG Lei, ZHOU Shukui, CHEN Yongji.
The value of 18 F-PSMA-1007 PET/CT in accurate assessment of newly diagnosed prostate cancer and its impact on clinical treatment decisions
[J]. China Oncology, 2020, 30(3): 231-236.
|
[11] |
ZHOU Jian, ZHANG Chaoyang, SUN Wei, YANG Jun, ZHANG Zhichao, QI Xiaohong.
Effects of miR-503 targeting TLR4 on drug resistance to docetaxel in prostate cancer
[J]. China Oncology, 2020, 30(11): 858-864.
|
[12] |
WANG Baohua, SHA Yuting, HE Fengdie, WU Jing.
The application of prostate-specific antigen in prostate cancer early detection in Chinese population: a Meta-analysis
[J]. China Oncology, 2020, 30(11): 879-886.
|
[13] |
CHEN Yang,YANG Qingsong,LU Jianping .
Differentiation of central gland prostate cancer from benign prostatic hyperplasia by using monoexponential and biexponential DWI models
[J]. China Oncology, 2019, 29(8): 583-589.
|
[14] |
ZHANG Neng, SU Peng, CHEN Shulian, LI Xiaoguang, HUANG Xiang, LUO Xu.
Expression of finger protein zinc finger protein ZIC2 and its effect on cell proliferation and apoptosis in prostate cancer
[J]. China Oncology, 2019, 29(4): 250-256.
|
[15] |
LIU Yongzhi, ZHAO Yonghua, JIANG Hai, BAO Liping, WU Wei, SUN Qiang, JIANG Huichuan, JIA Zhaobo, HAO Shichao.
Clinicopathological characteristics and survival analysis of patients with mucinous breast carcinoma based on SEER database
[J]. China Oncology, 2019, 29(12): 955-960.
|